Announcements Trials
Browse Landscape

Status

Completed 2Not yet recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 26Observational 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 3Neoplasms 2Recurrent Squamous Cell Lung Carcinoma 1

Interventions

Surveys and Questionnaires 70Blood Specimen Collection 60palbociclib 37Trastuzumab 31Letrozole 26Immunohistochemistry 26Drug Therapy 24Anastrozole 24Radiotherapy 21Gene Expression Profiling 20Amplified Fragment Length Polymorphism Analysis 20Mastectomy, Segmental 19Biopsy 19Tamoxifen 18exemestane 17Interviews as Topic 17ribociclib 16Mastectomy 16Fulvestrant 16Paclitaxel 15Magnetic Resonance Spectroscopy 15Psychiatric Rehabilitation 14High-Energy Shock Waves 14Polymerase Chain Reaction 13Observation 13Microarray Analysis 13Capecitabine 13trastuzumab deruxtecan 12Neoadjuvant Therapy 12Specimen Handling 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Observational × Breast Neoplasms × talazoparib × Clear all
NCT04982848 2025-11-18

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Pfizer

Not yet recruiting
600 enrolled
Breast

Breast Neoplasms

NCT05141708 2024-02-16

Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m

Pfizer

Completed
33 enrolled 9 charts
Breast

Breast Neoplasms

NCT04987931 2024-01-22

Real-World Outcomes of US Talazoparib-Treated Patients With Locally Advanced or Metastatic Breast Cancer

Pfizer

Completed
84 enrolled 11 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡